Necrotising fasciitis (also searched as necrotizing fasciitis, Fournier's gangrene, Fournier gangrene, Meleney's gangrene, hospital gangrene, streptococcal gangrene, ICD-10: M72.6) is a devastating, rapidly progressive bacterial infection targeting the deep fascial planes and subcutaneous tissue, accompanied by severe systemic toxicity and high mortality rates 1,2,5. The disease process typically initiates via cutaneous disruption or haematogenous seeding, allowing pathogenic bacteria to proliferate along fascial boundaries where poor vascular supply limits immune cell recruitment 6,7. Rapid local destruction is driven by bacterial exotoxins and enzymes that induce microvascular thrombosis, tissue ischemia, and liquefactive necrosis 5,7. Prompt clinical recognition remains challenging because early cutaneous manifestations often mimic benign cellulitis, frequently disguising the underlying deep destruction until extensive necrosis has occurred 3,5. Diagnosis is supported by clinical assessment, biochemical risk stratification tools such as the Laboratory Risk Indicator for Necrotising Fasciitis (LRINEC) score, and definitive surgical exploration 5. Management mandates emergency surgical debridement, aggressive haemodynamic resuscitation, and broad-spectrum antimicrobial therapy 5,7.

Etiology & Risk Factors

  • Microbiology (Type I - Polymicrobial): Typically caused by a synergistic mixture of aerobic and anaerobic organisms (e.g., Escherichia coli, Bacteroides fragilis, Enterococcus species, and Staphylococcus aureus), frequently isolated in patients with underlying comorbidities such as diabetes mellitus or peripheral vascular disease 1,7.
  • Microbiology (Type II - Monomicrobial): Predominantly caused by Group A Streptococcus (Streptococcus pyogenes), alone or in combination with Staphylococcus aureus (including methicillin-resistant strains), accounting for rapidly progressive infections in otherwise healthy individuals following minor trauma or surgery 1,3,5.
  • Microbiology (Type III & IV): Includes marine vibrio species (e.g., Vibrio vulnificus) acquired through seawater exposure or ingestion of raw seafood, as well as fungal necrotising infections in severely immunocompromised hosts 1.
  • Systemic Risk Factors: Diabetes mellitus (the most frequent comorbidity), chronic kidney disease, severe peripheral vascular disease, immunosuppression (malignancy, HIV, systemic chemotherapy, corticosteroid therapy), cirrhosis, and advanced age 1,7.
  • Local Predisposing Factors: Recent surgical incisions, perianal abscesses, cutaneous ulcers, minor blunt or penetrating trauma, insect bites, intravenous drug use, and burns 3,7.

Pathophysiology

The pathogenesis of necrotising fasciitis begins when bacterial pathogens enter the subcutaneous space through cutaneous breaches, mucous membranes, or minor skin trauma 3,7. Once established within the superficial fascial compartment, bacteria proliferate rapidly due to the relative avascularity of the fascial planes, which limits both humoral immune responses and systemic antibiotic penetration 6. As the organisms multiply, they release potent exotoxins, superantigens (such as streptococcal pyrogenic exotoxins A and B), and tissue-destroying enzymes (hyaluronidases, proteases, and lipases) that break down extracellular matrix proteins and facilitate lateral dissection along fascial layers 5. The host inflammatory response triggered by these bacterial toxins results in intense capillary leak, interstitial edema, microvascular thrombosis, and local tissue ischemia 5,7. This ischemic cascade leads to rapid liquefactive and coagulative necrosis of the superficial fascia and overlying subcutaneous fat, whilst sparing the deeper muscular layers initially 6. Because cutaneous nerves undergo ischemic and toxic destruction, the overlying skin may paradoxically lose superficial sensation late in the course, while systemic absorption of bacterial products and inflammatory cytokines precipitates severe systemic inflammatory response syndrome (SIRS), distributive shock, multi-organ dysfunction syndrome (MODS), and death if unaddressed 1,5,7.

Necrotising fasciitis (LRINEC score) — Pathophysiological Cascade & Clinical Flowchart 1 Primary Insult & Bacterial Inoculation Minor trauma or mucosal breach introduces polymicrobial or monomicrobial flora into subcutaneous planes. 2 Rapid Bacterial Proliferation & Toxin Release Exotoxins (e.g., streptococcal pyrogenic exotoxins) provoke massive local cytokine release and microvascular thrombosis. 3 Fascial Ischemia & Necrosis Thrombosis of nutrient vessels supplying the superficial fascia leads to ischemic necrosis of overlying skin and underlying layers. 4 Clinical Deterioration & Systemic Toxicity Severe systemic inflammatory response syndrome (SIRS), hemodynamic instability, and organ hypoperfusion ensue. 5 Surgical Intervention & Critical Care Immediate radical debridement, targeted antibiotics, and intensive resuscitation halt further tissue destruction.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients classically present with rapidly escalating local pain that is markedly out of proportion to physical examination findings 1,5. Initial symptoms may include localized tenderness, malaise, fever, rigors, and a sensation of tightness or swelling in the affected extremity, truncal region, or head and neck area 3,7.
  • Physical Examination & Named Clinical Signs: Early physical examination reveals non-specific erythema, warmth, and localized soft tissue swelling that rapidly extends beyond visible skin margins 3. As the disease progresses within 24 to 48 hours, the skin develops tense, wood-like induration, purpuric bullae or blisters containing serosanguinous or dark fluid, crepitus (due to gas-producing organisms), and areas of patchy cutaneous anesthesia progressing to cutaneous gangrene and necrosis 3,5. Signs of systemic toxicity—such as tachycardia, tachypnoea, hypotension, altered mental status, and oliguria—indicate progression to septic shock 7.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationSurgical exploration demonstrating a lack of fascial resistance to finger dissection (finger sweep test), grey necrotic fascial planes, and foul-smelling 'dishwater' fluid 5,7.
Laboratory PanelMarkedly elevated leukocytosis (often exceeding $15,000-30,000/\mu\text{L}$ with a left shift), acute kidney injury (elevated creatinine and urea), elevated serum lactate indicating tissue hypoperfusion, severe hyponatremia ($<135\text{ mmol/L}$), and elevated C-reactive protein ($>150\text{ mg/L}$) 5,7.
Imaging / Radiology (X-ray, US, CT, MRI)Plain radiography may reveal soft tissue gas along fascial planes; computed tomography (CT) with intravenous contrast demonstrates fascial thickening, fluid collections, subcutaneous gas, and non-enhancing necrotic fascia; ultrasound shows subcutaneous thickening and cobblestoning with deep fascial fluid accumulation; MRI demonstrates marked hyperintensity in deep fascial planes on T2-weighted images with fluid tracking, though imaging should never delay surgical exploration 5.
ECG / Histopathology / ProceduralElectrocardiography evaluates baseline cardiac rhythm and potential myocardial ischemia secondary to severe sepsis; histopathology confirms acute suppurative fasciitis with extensive necrosis of subcutaneous tissue, microvascular thrombosis, and intense neutrophilic infiltration accompanied by Gram stain visualization of causative organisms 1,7.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
LRINEC Score: C-Reactive Protein$<150\text{ mg/L} = 0\text{ points}$; $\ge 150\text{ mg/L} = 4\text{ points}$ 5.
LRINEC Score: Total White Blood Cell Count$<15.0 \times 10^3/\mu\text{L} = 0\text{ points}$; $15.0 - 25.0 \times 10^3/\mu\text{L} = 1\text{ point}$; $>25.0 \times 10^3/\mu\text{L} = 2\text{ points}$ 5.
LRINEC Score: Hemoglobin Concentration$>13.5\text{ g/dL} = 0\text{ points}$; $11.0 - 13.5\text{ g/dL} = 1\text{ point}$; $<11.0\text{ g/dL} = 2\text{ points}$ 5.
LRINEC Score: Serum Sodium Level$\ge 135\text{ mmol/L} = 0\text{ points}$; $<135\text{ mmol/L} = 2\text{ points}$ 5.
LRINEC Score: Serum Creatinine Level$\le 1.6\text{ mg/dL} (\le 141\text{-}\mu\text{mol/L}) = 0\text{ points}$; $>1.6\text{ mg/dL} (> 141\text{-}\mu\text{mol/L}) = 2\text{ points}$ 5.
LRINEC Score: Serum Glucose Level$\le 180\text{ mg/dL} (\le 10\text{ mmol/L}) = 0\text{ points}$; $>180\text{ mg/dL} (> 10\text{ mmol/L}) = 1\text{ point}$ 5.
LRINEC Risk StratificationScore 0 - 5: Low risk ($<50\%$ probability); Score 6 - 7: Intermediate risk ($50-75\%$ probability); Score $\ge 8$: High risk ($>75\%$ probability of necrotising fasciitis requiring urgent surgical intervention) 5.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Cellulitis / ErysipelasCharacterised by localized erythema, warmth, and tenderness without systemic toxicity or severe disproportionate pain; lacks fascial gas, rapid crepitus, or bullae; responds rapidly to standard outpatient or inpatient antibiotic therapy without requiring surgical debridement 3.
Deep Vein Thrombosis (DVT)Presents with unilateral limb swelling, pain, and erythema, but lacks cutaneous blistering, crepitus, or necrotic changes; diagnosed via compression ultrasonography showing venous filling defects 1.
PyomyositisInfection localized primarily to skeletal muscle rather than superficial fascial planes; typically presents with painful muscle abscesses, usually associated with Staphylococcus aureus bacteraemia, demonstrated on MRI or CT showing intramuscular fluid collections 1,7.
Contact Dermatitis / Severe Drug EruptionPresents with symmetrical pruritic or blistering rashes, often with clear exposure history or drug ingestion; lacks the severe systemic toxicity, wood-like fascial induration, and rapid progression characteristic of necrotising fasciitis 3.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate multidisciplinary resuscitation involving emergency medicine, general surgery, and intensive care; secure a definitive airway if respiratory compromise occurs, establish large-bore intravenous access, initiate aggressive fluid resuscitation with balanced crystalloids to restore tissue perfusion, and administer targeted vasopressors (e.g., norepinephrine) for persistent septic shock 5,7.
  • First-Line Medical / Pharmacological Therapy: Empiric broad-spectrum intravenous antimicrobial therapy must be initiated immediately after blood cultures are drawn. Adult dosing regimen: Vancomycin ($15\text{-}20\text{ mg/kg}$ IV every 8 to 12 hours, targeting trough levels of $15\text{-}20\text{ mcg/mL}$) combined with a broad-spectrum antipseudomonal beta-lactam such as Piperacillin-Tazobactam ($4.5\text{ g}$ IV every 6 hours) or Meropenem ($1\text{ g}$ IV every 8 hours). Addition of Clindamycin ($600\text{-}900\text{ mg}$ IV every 8 hours) is strongly recommended for its anti-toxin properties, particularly in suspected Group A streptococcal or staphylococcal infections to suppress bacterial protein synthesis 5,7.
  • Surgical / Interventional Indications: Emergent, radical surgical debridement of all necrotic tissue, fascia, and overlying non-viable skin is the definitive treatment and must not be delayed for imaging or laboratory results 5,7. Subsequent planned "second-look" surgical debridements every 24 to 48 hours are routinely required in an intensive care setting until all active tissue necrosis has ceased and healthy granulation tissue appears, followed by delayed primary closure, skin grafting, or reconstructive flap procedures 5,7.

Complications & Prognosis

  • Acute Complications: Septic shock, multi-organ dysfunction syndrome (MODS), acute kidney injury requiring renal replacement therapy, disseminated intravascular coagulation (DIC), severe electrolyte and acid-base disturbances, extensive tissue loss necessitating amputation or disfigurement, and prolonged mechanical ventilation 1,5,7.
  • Prognosis & Mortality Data: Mortality rates remain exceptionally high, frequently exceeding $30\% to 50\%$ overall, and approaching $100\%$ when treatment is delayed or when complicated by profound septic shock, advanced age, extensive truncal involvement, or underlying immunodeficiency 5. Key prognostic determinants include promptness of initial surgical debridement, adequacy of antimicrobial coverage, control of underlying comorbidities, and aggressive critical care management 5,7.